Subsequently, interrogation of publically available data sets (Basso et al, 2005) for 5 of these 6 genes (probes were unavailable for LYAR) confirmed low or absent expression in normal B-cell subsets and high expression in either indolent (NUMA1, MECP2, STMN2) or aggressive lymphoid malignancies (H2AFY, CYCLON), including BL, DLBCL and primary effusion lymphoma (PEL), respectively (Fig 1C). Here, LYAR is linked to diffuse large B-cell lymphoma.